Alex Kane - PTC Therapeutics Investor Officer
| PTCT Stock | USD 43.88 1.23 2.73% |
Insider
Alex Kane is Investor Officer of PTC Therapeutics
| Address | 100 Corporate Court, South Plainfield, NJ, United States, 07080 |
| Phone | 908 222 7000 |
| Web | https://www.ptcbio.com |
PTC Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.0515) % which means that it has lost $0.0515 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (77.4012) %, meaning that it created substantial loss on money invested by shareholders. PTC Therapeutics' management efficiency ratios could be used to measure how well PTC Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 0.80 in 2024, whereas Return On Tangible Assets are likely to drop (0.46) in 2024. At this time, PTC Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 2.2 B in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 1 B in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Igor Bilinsky | Iovance Biotherapeutics | 51 | |
| Remy Sukhija | Madrigal Pharmaceuticals | 52 | |
| Robert Waltermire | Madrigal Pharmaceuticals | 60 | |
| Todd MD | Hepion Pharmaceuticals | 55 | |
| Sharen Pyatetskaya | Hepion Pharmaceuticals | ||
| Jenna Cohen | Blueprint Medicines Corp | N/A | |
| Tracey Esq | Blueprint Medicines Corp | 56 | |
| David Glynn | Krystal Biotech | N/A | |
| BSc BSc | Hepion Pharmaceuticals | 66 | |
| Andreas Orth | Krystal Biotech | 54 | |
| JD MBA | Blueprint Medicines Corp | 51 | |
| Ryan Brown | Sarepta Therapeutics | 46 | |
| Alexis AM | Blueprint Medicines Corp | 52 | |
| Dr MBA | Blueprint Medicines Corp | 54 | |
| Launa Aspeslet | Hepion Pharmaceuticals | N/A | |
| Gloria Lin | Krystal Biotech | N/A | |
| Daren Ure | Hepion Pharmaceuticals | N/A | |
| Howard MBA | Iovance Biotherapeutics | 64 | |
| Paul MD | Madrigal Pharmaceuticals | 81 | |
| William Ciambrone | Sarepta Therapeutics | 60 | |
| Katherine Tuminello | Krystal Biotech | N/A | |
Management Performance
| Return On Equity | -77.4 | ||||
| Return On Asset | -0.0515 |
PTC Therapeutics Leadership Team
Elected by the shareholders, the PTC Therapeutics' board of directors comprises two types of representatives: PTC Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PTC. The board's role is to monitor PTC Therapeutics' management team and ensure that shareholders' interests are well served. PTC Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PTC Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christine Utter, Principal Financial Officer, Principal Accounting Officer, Treasurer | ||
| Christine CPA, Chief VP | ||
| Lee MD, Executive Officer | ||
| Ellen Welch, Chief Officer | ||
| FACS FACS, Chief Officer | ||
| Mark Boulding, Chief Legal Officer and Executive VP | ||
| Stuart Peltz, Co-Founder, CEO and Executive Director | ||
| Alex Kane, Investor Officer | ||
| Mark JD, Executive Officer | ||
| Linda Carter, Senior Officer | ||
| Eric Pauwels, Chief Officer | ||
| Emily Hill, Principal Financial Officer, Treasurer | ||
| FACS MD, CEO Director | ||
| Neil Almstead, Executive VP of Research, Pharmaceutical Operations and Technology | ||
| Dawn Svoronos, Director | ||
| Hege SollieZetlmayer, Senior Resources | ||
| Pierre MS, Chief Officer | ||
| Jane Baj, Vice Communications | ||
| John Baird, Chief CEO | ||
| Allan Jacobson, Co-Founder, Chairman of Scientific Advisory Board, Director and Member of Nominating and Corporate Governance Committee |
PTC Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is PTC Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -77.4 | ||||
| Return On Asset | -0.0515 | ||||
| Profit Margin | (0.50) % | ||||
| Operating Margin | (0.26) % | ||||
| Current Valuation | 2.77 B | ||||
| Shares Outstanding | 77.13 M | ||||
| Shares Owned By Insiders | 2.34 % | ||||
| Shares Owned By Institutions | 97.66 % | ||||
| Number Of Shares Shorted | 4.67 M | ||||
| Price To Earning | (5.67) X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for PTC Stock Analysis
When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.